biologic

Toujeo

insulin glargine

Loss of exclusivityFebruary 2027projected — 12-year biologic exclusivity estimate
CompanySanofi-Aventis U.S. LLC

Drug detail

Brand nameToujeo
Active ingredientinsulin glargine
Strength450UNITS/1.5ML (300UNITS/ML)
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalFebruary 2015
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Toujeo patent cliff — loss of exclusivity February 2027 | CliffBio